BETOPTIC PILO
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BETOPTIC PILO by Alcon is clinical pharmacology betaxolol hydrochloride, a cardioselective (beta 1 ) adrenoceptor antagonist, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Approved for elevated intraocular pressure in patients with primary open-angle glaucoma, ocular hypertension. First approved in 1997.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Betaxolol hydrochloride, a cardioselective (beta 1 ) adrenoceptor antagonist, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output…
Indications (2)
Worked on BETOPTIC PILO at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.